Apellis Pharmaceuticals Inc (APLS)
41.30
-0.70
(-1.67%)
USD |
NASDAQ |
May 17, 16:00
41.30
0.00 (0.00%)
After-Hours: 20:00
Apellis Pharmaceuticals Enterprise Value: 4.865B for May 16, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 16, 2024 | 4.865B |
| May 15, 2024 | 4.855B |
| May 14, 2024 | 4.767B |
| May 13, 2024 | 4.987B |
| May 10, 2024 | 4.863B |
| May 09, 2024 | 4.928B |
| May 08, 2024 | 4.901B |
| May 07, 2024 | 5.095B |
| May 06, 2024 | 5.691B |
| May 03, 2024 | 5.527B |
| May 02, 2024 | 5.531B |
| May 01, 2024 | 5.356B |
| April 30, 2024 | 5.127B |
| April 29, 2024 | 5.570B |
| April 26, 2024 | 5.815B |
| April 25, 2024 | 5.581B |
| April 24, 2024 | 5.823B |
| April 23, 2024 | 5.677B |
| April 22, 2024 | 5.546B |
| April 19, 2024 | 5.532B |
| April 18, 2024 | 5.530B |
| April 17, 2024 | 5.593B |
| April 16, 2024 | 6.053B |
| April 15, 2024 | 6.014B |
| April 12, 2024 | 6.049B |
| Date | Value |
|---|---|
| April 11, 2024 | 6.527B |
| April 10, 2024 | 6.662B |
| April 09, 2024 | 6.453B |
| April 08, 2024 | 6.294B |
| April 05, 2024 | 6.547B |
| April 04, 2024 | 6.564B |
| April 03, 2024 | 6.673B |
| April 02, 2024 | 6.522B |
| April 01, 2024 | 7.008B |
| March 31, 2024 | 6.895B |
| March 28, 2024 | 6.830B |
| March 27, 2024 | 6.795B |
| March 26, 2024 | 6.856B |
| March 25, 2024 | 6.438B |
| March 22, 2024 | 6.421B |
| March 21, 2024 | 6.568B |
| March 20, 2024 | 6.437B |
| March 19, 2024 | 6.605B |
| March 18, 2024 | 6.526B |
| March 15, 2024 | 6.584B |
| March 14, 2024 | 6.552B |
| March 13, 2024 | 6.658B |
| March 12, 2024 | 6.796B |
| March 11, 2024 | 7.060B |
| March 08, 2024 | 7.173B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
883.80M
Minimum
May 20 2019
10.19B
Maximum
Jun 13 2023
4.119B
Average
3.820B
Median
Enterprise Value Benchmarks
| Inspire Medical Systems Inc | 4.284B |
| Sarepta Therapeutics Inc | 12.40B |
| Blueprint Medicines Corp | 6.269B |
| Alnylam Pharmaceuticals Inc | 17.78B |
| Cytokinetics Inc | 6.241B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -66.42M |
| Revenue (Quarterly) | 172.32M |
| Total Expenses (Quarterly) | 234.42M |
| EPS Diluted (Quarterly) | -0.54 |
| Gross Profit Margin (Quarterly) | 88.27% |
| Profit Margin (Quarterly) | -38.55% |
| Earnings Yield | -8.38% |
| Normalized Earnings Yield | -8.378 |